| 张 灵,范 凌,郝 杰,张 阳,靳艳丽,高炳华.弥漫大B细胞淋巴瘤患者Th22细胞及其细胞因子的表达及临床意义[J].现代生物医学进展英文版,2023,(21):4187-4191. |
| 弥漫大B细胞淋巴瘤患者Th22细胞及其细胞因子的表达及临床意义 |
| Expression and Clinical Significance of Th22 cell and Its Cytokines in Patients with Diffuse Large B-cell Lymphoma |
| Received:June 01, 2023 Revised:June 24, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.21.036 |
| 中文关键词: 弥漫大B细胞淋巴瘤 Th22 IL-22 IL-13 IL-6 TNF-α 临床意义 |
| 英文关键词: Diffuse large B-cell lymphoma Th22 IL-22 IL-13 IL-6 TNF-α Clinical significance |
| 基金项目:河北省医学科学研究课题计划项目（20231414）；张家口市科技计划自筹经费项目（2221074D） |
|
| Hits: 365 |
| Download times: 250 |
| 中文摘要: |
| 摘要 目的：探讨弥漫大B细胞淋巴瘤（DLBCL）患者辅助性T细胞（Th）22细胞及其细胞因子的表达及临床意义。方法：选择2019年6月到2021年6月河北北方学院附属第一医院收治的121例DLBCL患者（DLBCL组）和70例健康志愿者（对照组）。治疗前、后检测外周血Th22细胞百分比及其细胞因子-白细胞介素（IL）-22、IL-13、 IL-6、肿瘤坏死因子（TNF）-α水平。比较DLBCL组和对照组及不同AnnArbor临床分期、国际预后指数（IPI）评分、Hans免疫分型以及疗效的DLBCL患者外周血Th22百分比及血清IL-22、 IL-13、 IL-6、TNF-α水平差异。结果：DLBCL组外周血Th22细胞百分比、血清IL-22、IL-13、IL-6、TNF-α水平高于对照组（P＜0.05）。Ⅲ～Ⅳ期组、高中危组和高危组、非GCB型组治疗前外周血Th22细胞百分比、血清IL-22、IL-13、IL-6、TNF-α水平分别高于Ｉ～Ⅱ期组、低危组和低中危组、GCB型组（P均＜0.05）。121例患者中判定治疗无效者有39例，根据疗效将患者分为无效组（39例）和有效组（82例），无效组治疗后外周血Th22细胞百分比、血清IL-22、IL-13、IL-6、TNF-α水平与治疗前比较无显著变化（P＞0.05），且无效组治疗前、后高于有效组（P＜0.05）。结论：DLBCL患者外周血中Th22百分比以及血清IL-22、IL-13、IL-6、TNF-α水平升高，且与高AnnArbor临床分期、高IPI评分、非GCB型以及临床治疗效果较差有关。临床可通过监测上述指标水平以调整治疗方案，提高治疗的有效率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression and clinical significance of helper T (Th) 22 cell and its cytokines in patients with diffuse large B-cell lymphoma (DLBCL). Methods: 121 patients with DLBCL (DLBCL group) and 70 healthy volunteers (control group) who were admitted to the First Affiliated Hospital of Hebei North University from June 2019 to June 2021 were selected. The percentage of Th22 cell and the levels of cytokines - interleukin (IL-22), IL-13, IL-6 and tumor necrosis factor (TNF)-α in peripheral blood before and after treatment were detected. The difference of levels of the percentage of Th22 and serum IL-22, IL-13, IL-6 and TNF-α were compared between DLBCL group and control group, different AnnArbor clinical stages, International Prognosis Index (IPI) score and Hans immune classification and different efficacy of patients with DLBCL. Results: The percentage of Th22 cell in peripheral blood and the levels of serum of IL-22, IL-13, IL-6 and TNF-α in the DLBCL group were higher than those in the control group (P＜0.05). The percentage of Th22 cell in peripheral blood, the levels of serum IL-22, IL-13, IL-6 and TNF-α in the stage Ⅲ～Ⅳ group, high-medium risk group and high risk group, and non-GCB group before treatment were higher than those in the stage I～ Ⅱ group, low risk group and low-medium risk group and GCB group, respectively (all P＜0.05). 39 of 121 patients were judged to be non-responders to treatment, and the patients were divided into the ineffective group(n=39) and effective group(n=82) based on efficacy. The percentage of Th22 cell in peripheral blood and the levels of serum IL-22, IL-13, IL-6 and TNF-α in the ineffective group after treatment had no significant changes compared with those before treatment(P＞0.05), and the ineffective group before and after treatment were higher than the effective group(P＜0.05). Conclusion: The percentage of Th22 in peripheral blood and the levels of serum IL-22, IL-13, IL-6 and TNF-α in patients with DLBCL increased, which are associated with high AnnArbor clinical stages, high IPI score, non-GCB type and poor clinical treatment effect. The clinic can adjust the treatment regimen by monitoring the levels of the above indicators and improve the effective rate of treatment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
